Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC (IV) in colorectal cancer, run by Beijing Biotech, now recruiting.
Overview
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07462650 by Beijing Biotech, with 48 participants planned, started 2026-02-01 and due to reach its primary completion in 2027-12-21. Interventions recorded: EB-DUO-CAR-NK-CEA/GCC (IV).
Similar pages
not linked directly; found by shared links- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Clinical Study of Arfolitixorin in Patients With mCRC
Shares Colorectal cancer and the tag pipeline.